A surprising discovery during kidney research has led scientists to a possible new treatment for one of the world’s fastest-growing liver diseases.
Researchers at the Medical University of South Carolina have found that a common asthma medicine called formoterol may help reverse liver damage linked to MASH, a serious form of fatty liver disease.
The research was published in the journal npj Metabolic Health and Disease.
The discovery happened unexpectedly. Scientists were not originally studying liver disease at all. They were investigating whether formoterol could protect the kidneys from damage caused by diabetes.
During experiments involving mice, the researchers noticed something unusual. The animals treated with the asthma drug also seemed to have healthier livers.
This observation led the research team to launch a separate study focused on fatty liver disease and how the drug might affect the liver.
MASH, which stands for metabolic dysfunction-associated steatohepatitis, develops when fat builds up inside the liver and triggers inflammation and injury.
Over time, this ongoing damage can lead to liver scarring, liver failure, and even liver cancer. MASH has become one of the leading reasons for liver transplantation in many countries.
The disease is closely tied to modern health problems such as obesity, diabetes, insulin resistance, and poor metabolic health. As rates of obesity continue to rise worldwide, doctors expect MASH to become an even larger public health problem in the coming decades.
One major challenge is that fatty liver disease often develops silently. Many people feel normal for years without realizing their liver is being damaged. By the time symptoms appear, the disease may already be advanced.
At present, treatment options remain limited. Doctors usually recommend weight loss, healthier eating, exercise, and diabetes management. Recently approved medications can help some patients, but they do not completely reverse the disease and may cause side effects.
That is why the new findings are generating interest. Formoterol has already been prescribed safely for many years to treat asthma and chronic obstructive pulmonary disease. It works by opening the airways and helping people breathe more easily.
Researchers tested the drug in mice fed a high-fat diet designed to produce MASH-like liver damage. They found that the treatment appeared to reverse fatty liver disease in several ways.
The scientists also explored how the drug might be working inside the body. Their findings suggest that formoterol may improve the function of mitochondria, tiny structures inside cells that create energy.
Mitochondria are extremely important for healthy organs. When they stop functioning properly, cells struggle to manage energy and can become damaged. This problem is common in metabolic diseases such as diabetes and fatty liver disease.
According to the researchers, formoterol seemed to stimulate mitochondrial biogenesis, a process that increases the number and function of mitochondria. In simple terms, the drug appeared to help cells produce energy more efficiently and recover from injury.
The team also examined real-world patient data. They reviewed records from people already taking beta-2 agonist drugs like formoterol for breathing conditions. These patients appeared to have lower rates of serious liver problems, including cirrhosis and death.
Although this does not prove the medication directly protected the liver, it supports the idea that the drug may influence metabolic health in important ways.
Dr. Joshua Lipschutz, one of the study authors, said researchers were encouraged by the results because the drug did more than simply slow disease progression. In the mouse studies, it appeared to actually reverse liver damage at several levels.
Scientists are now running a clinical trial involving patients with diabetic kidney disease. Since more than half of people with diabetic kidney disease also have MASH, the trial may provide valuable information about both conditions.
Researchers hope this could eventually lead to a treatment that targets multiple metabolic diseases at the same time.
Another important advantage is cost and speed. Developing a completely new medicine can take more than a decade. Because formoterol is already approved and widely used, the path toward clinical use may be much faster if future trials are successful.
Still, experts urge caution. Many promising treatments work well in mice but fail in human studies. Scientists still need to answer important questions about the best dose, long-term safety, and whether inhaled formoterol delivers enough medication to affect organs like the liver and kidneys.
The researchers also emphasized that no medicine is entirely without risk. Even commonly used drugs can cause side effects or complications in certain patients.
Despite these uncertainties, the study highlights the growing importance of metabolic health research. Scientists are increasingly discovering that diseases affecting the liver, kidneys, heart, and blood sugar are deeply connected.
This research also shows how unexpected discoveries can sometimes open entirely new directions in medicine. What began as kidney research may now help scientists develop new ways to fight one of the world’s most serious liver diseases.
The study was published in npj Metabolic Health and Disease.
The findings are important because they suggest that an inexpensive and familiar asthma medication could potentially become part of future treatment strategies for MASH and related metabolic diseases.
However, patients should understand that the research remains early and experimental. Doctors are not yet recommending formoterol as a treatment for fatty liver disease. Larger human trials will be needed to confirm whether the benefits seen in mice and observational patient data truly apply to people with MASH.
If you care about liver health, please read studies about simple habit that could give you a healthy liver, and common diabetes drug that may reverse liver inflammation.
For more information about health, please see recent studies about simple blood test that could detect your risk of fatty liver disease, and results showing this green diet may strongly lower non-alcoholic fatty liver disease.
Source: Medical University of South Carolina.
